Vivani Medical (NASDAQ:VANI) Director Gregg Williams Buys 1,587,301 Shares

Posted by George Bondi on Jun 17th, 2026

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the acquisition, the director owned 36,119,086 shares in the company, valued at $45,510,048.36. This trade represents a 4.60% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

On Friday, May 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26.
On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26.

Vivani Medical Trading Up 3.5%

Shares of Vivani Medical stock opened at $1.17 on Wednesday. The company has a 50 day moving average of $1.21 and a 200-day moving average of $1.25. Vivani Medical, Inc. has a 1-year low of $0.92 and a 1-year high of $1.92. The company has a market cap of $100.90 million, a PE ratio of -2.92 and a beta of 2.31.

Vivani Medical (NASDAQ:VANI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). Research analysts forecast that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Vivani Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in VANI. Citadel Advisors LLC acquired a new position in Vivani Medical in the 3rd quarter valued at approximately $26,000. Susquehanna International Group LLP increased its position in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares during the period. Geode Capital Management LLC increased its position in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after acquiring an additional 105,398 shares during the period. Renaissance Technologies LLC increased its position in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after acquiring an additional 53,127 shares during the period. Finally, Jane Street Group LLC acquired a new position in Vivani Medical in the 4th quarter valued at approximately $60,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VANI has been the subject of a number of research analyst reports. HC Wainwright lowered their price objective on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.50.

Check Out Our Latest Report on Vivani Medical

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.